What effects can intrapartum antimicrobial use have on the neonatal microbiome development? And could they impact in long-term health?
To round up 2018, we asked our Expert panel to choose their top papers from across the year. Here, you can discover the articles they selected and read about and the reasons why!
The International Congress of the European Respiratory Society, 15–19 September, Paris (France), is the largest respiratory medicine meeting in the world. Find out about the latest research on non-tuberculous mycobacteria lung disease (NTM-LD) discussed at the 2018 congress in this report.
Antimicrobial resistance and sepsis are inherently interconnected issues, but are campaigns for antibiotic stewardship competing against sepsis awareness campaigns with regards to their messages on antibiotic use?
By carefully considering the characteristics of certain old and new antibiotics, it may be possible to overcome many bacterial resistance mechanisms, including when more than one is present.
In this article, the authors discuss their research using non-ribosome targeting tobramycin-based adjuvants to overcome the intrinsic resistance observed in bacteria, Pseudomonas aeruginosa.
In recent years, researchers have discovered the potential of CRISPR as an antimicrobial. In this blog post we explain the recent advances made in this field and the different approaches by which CRISPR can be used as a new weapon in the battle against antimicrobial resistance.
Gauri Godbole, from Public Health England, gives us an overview of recent advances and updates in the field of gastrointestinal infections – from the impact of the microbiome to the growing threat of antimicrobial resistance.
We take a look at the drugs that have been studied as treatments for confirmed prion diseases in humans – either in clinical trials, or on a compassionate, case-by-case basis – and look at what the future might hold for the treatment of prion diseases.